ATE194078T1 - Fenofibrat-vitamin-e-mischung und ihre therapeutische verwendung - Google Patents

Fenofibrat-vitamin-e-mischung und ihre therapeutische verwendung

Info

Publication number: ATE194078T1
Authority: AT; Austria
Prior art keywords: fenofibrate; vitamin; micronisate; mixture; therapeutic use
Prior art date: 1995-02-02

Application number

AT96400133T

Other languages

English (en)

Inventor

Alan Dunlap Edgar

Francois Bellamy

Original Assignee

Fournier Lab Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-02-02

Filing date

1996-01-19

Publication date

2000-07-15

1996-01-19 Application filed by Fournier Lab Sa filed Critical Fournier Lab Sa

2000-07-15 Application granted granted Critical

2000-07-15 Publication of ATE194078T1 publication Critical patent/ATE194078T1/de

Links

229960002297 fenofibrate Drugs 0.000 title abstract 8
-1 FENOFIBRATE VITAMIN Chemical class 0.000 title abstract 2
239000000203 mixture Substances 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1
229940088594 vitamin Drugs 0.000 title 1
229930003231 vitamin Natural products 0.000 title 1
235000013343 vitamin Nutrition 0.000 title 1
239000011782 vitamin Substances 0.000 title 1
YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 abstract 7
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
239000007787 solid Substances 0.000 abstract 2
239000004094 surface-active agent Substances 0.000 abstract 2
206010051113 Arterial restenosis Diseases 0.000 abstract 1
102000004895 Lipoproteins Human genes 0.000 abstract 1
108090001030 Lipoproteins Proteins 0.000 abstract 1
229930003427 Vitamin E Natural products 0.000 abstract 1
208000037849 arterial hypertension Diseases 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract 1
229930003799 tocopherol Natural products 0.000 abstract 1
229960001295 tocopherol Drugs 0.000 abstract 1
239000011732 tocopherol Substances 0.000 abstract 1
235000010384 tocopherol Nutrition 0.000 abstract 1
239000011709 vitamin E Substances 0.000 abstract 1
229940046009 vitamin E Drugs 0.000 abstract 1
235000019165 vitamin E Nutrition 0.000 abstract 1
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT96400133T 1995-02-02 1996-01-19 Fenofibrat-vitamin-e-mischung und ihre therapeutische verwendung ATE194078T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9501216A FR2730231B1 (fr)	1995-02-02	1995-02-02	Association de fenofibrate et de vitamine e, utilisation en therapeutique

Publications (1)

Publication Number	Publication Date
ATE194078T1 true ATE194078T1 (de)	2000-07-15

Family

ID=9475777

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT96400133T ATE194078T1 (de)	1995-02-02	1996-01-19	Fenofibrat-vitamin-e-mischung und ihre therapeutische verwendung

Country Status (10)

Country	Link
US (1)	US5880148A (de)
EP (1)	EP0724877B1 (de)
JP (1)	JP4746726B2 (de)
AT (1)	ATE194078T1 (de)
DE (1)	DE69608974T2 (de)
DK (1)	DK0724877T3 (de)
ES (1)	ES2148694T3 (de)
FR (1)	FR2730231B1 (de)
GR (1)	GR3034147T3 (de)
PT (1)	PT724877E (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7255877B2 (en)	1996-08-22	2007-08-14	Jagotec Ag	Fenofibrate microparticles
US6465016B2 (en)	1996-08-22	2002-10-15	Research Triangle Pharmaceuticals	Cyclosporiine particles
RU2186562C2 (ru)	1996-08-22	2002-08-10	Ресеч Трайангл Фармасьютикалс Лтд.	Композиции, представляющие собой микрочастицы веществ, нерастворимых в воде, и способ их изготовления
US20030129215A1 (en) *	1998-09-24	2003-07-10	T-Ram, Inc.	Medical devices containing rapamycin analogs
US6890546B2 (en) *	1998-09-24	2005-05-10	Abbott Laboratories	Medical devices containing rapamycin analogs
WO1999029300A1 (en) *	1997-12-10	1999-06-17	Rtp Pharma Inc.	Self-emulsifying fenofibrate formulations
US6979456B1 (en)	1998-04-01	2005-12-27	Jagotec Ag	Anticancer compositions
AU764001B2 (en)	1998-05-29	2003-08-07	Skyepharma Canada Inc.	Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
CN1221249C (zh)	1998-08-19	2005-10-05	斯凯伊药品加拿大公司	普鲁泊福的可注射水分散体
US20060240070A1 (en) *	1998-09-24	2006-10-26	Cromack Keith R	Delivery of highly lipophilic agents via medical devices
SK288117B6 (sk)	1998-11-20	2013-09-03	Skyepharma Canada Inc.	Rapidly dispersing solid dry therapeutic dosage form
US6368622B2 (en)	1999-01-29	2002-04-09	Abbott Laboratories	Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
GB0000710D0 (en) *	1999-02-06	2000-03-08	Zeneca Ltd	Drug combination
US6248363B1 (en) *	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19910682B4 (de) *	1999-03-10	2004-09-02	Dierkes, Jutta, Dr.	Verwendung eines Kombinationspräparates zur Therapie einer Fibrat-induzierten Hyperhomocysteinämie
CA2270306C (en) *	1999-04-27	2000-09-26	Bernard Charles Sherman	Pharmaceutical compositions comprising co-micronized fenofibrate
US6372251B2 (en)	1999-06-11	2002-04-16	Abbott Laboratories	Formulations comprising lipid-regulating agents
US20030236236A1 (en) *	1999-06-30	2003-12-25	Feng-Jing Chen	Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6982281B1 (en) *	2000-11-17	2006-01-03	Lipocine Inc	Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
WO2001021154A2 (en) *	1999-09-21	2001-03-29	Rtp Pharma Inc.	Surface modified particulate compositions of biologically active substances
FR2803203B1 (fr) *	1999-12-31	2002-05-10	Fournier Ind & Sante	Nouvelles formulations galeniques du fenofibrate
AU2001257115B2 (en)	2000-04-20	2005-01-27	Rtp Pharma Inc.	Improved water-insoluble drug particle process
TWI354568B (en) *	2000-09-20	2011-12-21	Jagotec Ag	Insoluble drug particle compositions with improved
US8586094B2 (en) *	2000-09-20	2013-11-19	Jagotec Ag	Coated tablets
AU2002221765B2 (en) *	2000-10-26	2006-09-07	Fournier Laboratories Ireland Limited	Combination of fenofibrate and coenzyme Q10 for the treatment of endothelial dysfunction
PL212952B1 (pl) *	2000-10-26	2012-12-31	Fournier Lab Ireland Ltd	Kompozycja farmaceutyczna zawierajaca fenofibrat i koenzym Q₁₀ oraz jej zastosowanie
US6982251B2 (en) *	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
KR20070120617A (ko)	2001-01-26	2007-12-24	쉐링 코포레이션	치환된 아제티딘온 화합물을 포함하는 약제학적 조성물
US7071181B2 (en)	2001-01-26	2006-07-04	Schering Corporation	Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US20060287254A1 (en) *	2001-01-26	2006-12-21	Schering Corporation	Use of substituted azetidinone compounds for the treatment of sitosterolemia
IL156445A0 (en)	2001-01-26	2004-01-04	Schering Corp	Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
NZ527408A (en) *	2001-02-22	2005-04-29	Skyepharma Canada Inc	Hydroxymethylglutarylcoenzyme A (HMG CoA) reductase inhibitor (or a statin) and a fibrate in a single effective oral dosage form to treat dyslipidaemia and dyslipoproteinaemia
GB0114532D0 (en) *	2001-06-14	2001-08-08	Jagotec Ag	Novel compositions
GB0119480D0 (en) *	2001-08-09	2001-10-03	Jagotec Ag	Novel compositions
US20080145402A1 (en) *	2001-09-10	2008-06-19	Abbott Cardiovascular Systems Inc.	Medical Devices Containing Rapamycin Analogs
EP1429756B1 (de) *	2001-09-21	2006-11-22	Schering Corporation	Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
US7053080B2 (en)	2001-09-21	2006-05-30	Schering Corporation	Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US20030212138A1 (en) *	2002-01-14	2003-11-13	Pharmacia Corporation	Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
US20030220374A1 (en) *	2002-01-14	2003-11-27	Pharmacia Corporation	Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
CA2481371A1 (en) *	2002-03-11	2003-09-18	Peter Zahradka	Use of ppar alpha agonists for the treatment of vascular and renal diseases
FR2845602B1 (fr) *	2002-10-11	2005-07-08	Servier Lab	Association entre un ligand des recepteurs actives par les proliferateurs de peroxisomes et un agent antioxydant et les compositions pharmaceutiques qui les contiennent
CA2504916A1 (en)	2002-11-06	2004-05-27	Schering Corporation	Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
AU2002356294A1 (en) *	2002-12-13	2004-07-09	Jagotec Ag	A topical nanoparticulate spironolactone formulation
US20040115287A1 (en) *	2002-12-17	2004-06-17	Lipocine, Inc.	Hydrophobic active agent compositions and methods
FR2851734B1 (fr) *	2003-02-28	2006-06-09	Galenix Innovations	Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede
WO2004081002A1 (en) *	2003-03-07	2004-09-23	Schering Corporation	Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
WO2004081004A1 (en) *	2003-03-07	2004-09-23	Schering Corporation	Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7459442B2 (en) *	2003-03-07	2008-12-02	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
DE602004018617D1 (de) *	2003-03-07	2009-02-05	Schering Corp	Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US20060003002A1 (en) *	2003-11-03	2006-01-05	Lipocine, Inc.	Pharmaceutical compositions with synchronized solubilizer release
JP2006273849A (ja) *	2005-03-02	2006-10-12	Aska Pharmaceutical Co Ltd	フェノフィブラート含有組成物
EP2327429B1 (de) *	2005-03-23	2014-09-17	Abbott Laboratories	Verabreichung stark lipophiler wirkstoffe mittels medizinischer vorrichtungen
CA2600407A1 (en) *	2005-03-30	2006-10-12	Teva Pharmaceutical Industries Ltd.	Fibrate compositions containing a surfactant mixture of peg-600 and poloxamer 407
CA2601372A1 (en) *	2005-03-30	2006-10-12	Teva Pharmaceutical Industries Ltd.	Improved formulations of fenofibrate containing menthol or peg/poloxamer
US20070148233A1 (en) *	2005-12-28	2007-06-28	Lerner E I	Pharmaceutical formulations of fenofibrate having improved bioavailability
EP1707197A1 (de)	2005-03-30	2006-10-04	Teva Pharmaceutical Industries Ltd.	Zusammensetzungen, welche Fenofibrat und eine Tensidmischung beinhaltet
JP4818637B2 (ja) *	2005-05-02	2011-11-16	日本メナード化粧品株式会社	低密度リポタンパク質（ｌｄｌ）酸化抑制剤
US20070015834A1 (en) *	2005-07-18	2007-01-18	Moshe Flashner-Barak	Formulations of fenofibrate containing PEG/Poloxamer
US20070015833A1 (en) *	2005-07-18	2007-01-18	Moshe Flashner-Barak	Formulations of fenofibrate containing menthol
ES2325450T3 (es)	2005-12-28	2009-09-04	Teva Pharmaceutical Industries Ltd	Formulaciones farmaceuticas de fenofibrato con una biodisponibilidad mejorada.
US8861813B2 (en) *	2008-03-13	2014-10-14	Mallinckrodt Llc	Multi-function, foot-activated controller for imaging system
US11304960B2 (en)	2009-01-08	2022-04-19	Chandrashekar Giliyar	Steroidal compositions
US20120076838A1 (en)	2009-05-27	2012-03-29	Samyang Biopharmaceuticals Corporation	Poorly soluble drug containing microsphere with improved bioavailabilty and method of preparing the same
US20110217369A1 (en) *	2009-09-03	2011-09-08	Ranbaxy Laboratories Limited	Fenofibrate compositions
US20180153904A1 (en)	2010-11-30	2018-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9034858B2 (en)	2010-11-30	2015-05-19	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9358241B2 (en)	2010-11-30	2016-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20120148675A1 (en)	2010-12-10	2012-06-14	Basawaraj Chickmath	Testosterone undecanoate compositions
WO2014091318A1 (en)	2012-12-11	2014-06-19	Lupin Atlantis Holdings, S.A.	Reduced dose pharmaceutical compositions of fenofibrate
ES2830352T3 (es)	2013-09-18	2021-06-03	Univ Georgetown	Tratamiento de enfermedad neurodegenerativa con fenofibrato y análogos del mismo
US9498485B2 (en)	2014-08-28	2016-11-22	Lipocine Inc.	Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en)	2014-08-28	2016-03-03	Lipocine Inc.	(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016205423A2 (en)	2015-06-15	2016-12-22	Lipocine Inc.	Composition and method for oral delivery of androgen prodrugs
CA3078723A1 (en)	2016-11-28	2018-05-31	Nachiappan Chidambaram	Oral testosterone undecanoate therapy
EP3824296B1 (de)	2018-07-20	2026-04-01	Lipocine Inc.	Orale pharmazeutische zusammensetzung mit testosterontridecanoat und/oder testosterondodecanoat zur behandlung von lebererkrankungen

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE792855A (fr) *	1971-12-16	1973-06-15	Ici Ltd	Compositions pharmaceutiques agissant sur le taux de cholesterol dans le sang
JPS57188587A (en) *	1981-05-15	1982-11-19	Tanabe Seiyaku Co Ltd	Thienyloxazolylacetic acid derivative and its preparation
DE3588023D1 (de) *	1984-01-28	1995-06-29	Roshdy Ismail	Mittel zur Behandlung von Herzerkrankungen.
EP0344820B1 (de) *	1984-01-28	1995-05-24	Roshdy Dr. Ismail	Mittel zur Behandlung von Herzerkrankungen
FR2602423B1 (fr) *	1986-08-08	1989-05-05	Ethypharm Sa	Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
US4859703A (en) *	1987-06-15	1989-08-22	Warner-Lambert Company	Lipid regulating compositions
FR2627696B1 (fr) *	1988-02-26	1991-09-13	Fournier Innovation Synergie	Nouvelle forme galenique du fenofibrate
JP3852621B2 (ja) *	1992-01-21	2006-12-06	あすか製薬株式会社	血管内皮細胞機能改善剤
US5662934A (en) *	1993-01-05	1997-09-02	Najarian; Thomas	Compositions and methods for lowering cholesterol while maintaining antioxidant levels
JP3848380B2 (ja) *	1993-12-14	2006-11-22	エーザイ・アール・アンド・ディー・マネジメント株式会社	α−トコフェロール誘導体の製造法

1995
- 1995-02-02 FR FR9501216A patent/FR2730231B1/fr not_active Expired - Fee Related
1996
- 1996-01-19 DK DK96400133T patent/DK0724877T3/da active
- 1996-01-19 AT AT96400133T patent/ATE194078T1/de active
- 1996-01-19 EP EP96400133A patent/EP0724877B1/de not_active Expired - Lifetime
- 1996-01-19 PT PT96400133T patent/PT724877E/pt unknown
- 1996-01-19 DE DE69608974T patent/DE69608974T2/de not_active Expired - Lifetime
- 1996-01-19 ES ES96400133T patent/ES2148694T3/es not_active Expired - Lifetime
- 1996-01-29 JP JP04787596A patent/JP4746726B2/ja not_active Expired - Fee Related
- 1996-02-02 US US08/594,658 patent/US5880148A/en not_active Expired - Lifetime
2000
- 2000-08-08 GR GR20000401842T patent/GR3034147T3/el unknown

Also Published As

Publication number	Publication date
DE69608974D1 (de)	2000-08-03
DK0724877T3 (da)	2000-10-16
JP4746726B2 (ja)	2011-08-10
PT724877E (pt)	2000-12-29
ES2148694T3 (es)	2000-10-16
GR3034147T3 (en)	2000-11-30
EP0724877B1 (de)	2000-06-28
DE69608974T2 (de)	2001-02-08
FR2730231B1 (fr)	1997-04-04
US5880148A (en)	1999-03-09
FR2730231A1 (fr)	1996-08-09
EP0724877A1 (de)	1996-08-07
JPH08253416A (ja)	1996-10-01

Publication	Publication Date	Title
DE69608974D1 (de)	2000-08-03	Fenofibrat-Vitamin-E-Mischung und ihre therapeutische Verwendung
MX9207224A (es)	1993-06-01	Apolipoproteina.
ATE76747T1 (de)	1992-06-15	Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
ATE399151T1 (de)	2008-07-15	2-ethyl und 2-ethyliden-19-nor-vitamin d- verbindungen
DE69520656D1 (de)	2001-05-17	Beschränkte 9-cis-Retinoide
DE10299012I1 (de)	2002-07-18	Porphyrine and Arzneimittel zur Krebsbehandlung
IL105244A0 (en)	1993-07-08	Compounds for treating a condition or disease in a human related to supranormal intracellular enzyme activity
ES2071339T3 (es)	1995-06-16	Agentes hipoglicemicos e hipocolesterolemicos de oxazolidindiona.
ES2090244T3 (es)	1996-10-16	Procedimiento para prevenir, estabilizar u ocasionar la regresion de la aterosclerosis usando una combinacion de un medicamento para disminuir el colesterol y un inhibidor de la ace.
ATE188704T1 (de)	2000-01-15	Phosphonsäurediester-derivat
DE69302883D1 (de)	1996-07-04	L-Carnitin- und Alkanoyl-L-Carnitin-Ester mit Glykolsäure oder ihre Ester und diese enthaltende pharmazeutische Zusammensetzungen zur Behandlung von Dermatosen
ES2052065T3 (es)	1994-07-01	Formulacion dispersable.
BR9713921A (pt)	2000-03-21	Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa
ATE258797T1 (de)	2004-02-15	Verwendung von amifostin
KR920002151A (ko)	1992-02-28	15-케토-프로스타글란딘 화합물에 의한 염증성 질환 치료
NO933321D0 (no)	1993-09-17	Nadh og nadph som legemiddel til behandling av mobus alzheimer
WO1994009785A3 (en)	1994-08-04	Methods and compositions of (+) doxazosin for the treatment of benign prostatic hyperplasia and atherosclerosis
EP1156050A3 (de)	2001-11-28	Substituierte tricyclische Verbindungen und deren Verwendung zur Behandlung von sPLA2-bedingten Erkrankungen
WO1999032098A3 (en)	1999-08-19	Combination of a ramba and a tocopherol
ATE356209T1 (de)	2007-03-15	Mutanten des thyroid-stimulierenden hormons
DK0602961T3 (da)	1998-03-16	Hudbehandlingssammensætning af lanolin/lanolinsyreestere
MX9403032A (es)	1995-01-31	Quinolil-dihidropiridinas condensadas, procedimiento para su fabricacion ysu uso en medicamentos.
CU22225A1 (es)	1995-01-31	Composicion farmacautica que contiene mezcla de alcoholes alifaticos primarios superiores para el tratamiento de hipercolesterolemia y la hiperlipoproteinemia tipo ii asi como estimulante de la conducta sexual en animales y humanos
WO2003045311A3 (en)	2003-11-20	Methods for inhibiting or suppressing stenosis of arteriovenous access fistulas and grafts
DE69018099D1 (de)	1995-05-04	Polyamin-Derivate als antineoplastische Mittel.